EFTA00589683Set 9
5p1,569w
Oncology Department at Johns Hopkins University. The department was trying to understand
how the KRAS gene in colon-cancer cells becomes activated after inhibitor-drug therapy,
making the cells resistant ... growth of colon-cancer cells, Nowak and his team
showed that the KRAS gene is not actually activated or "switched on" by inhibitor therapy;
rather, a small percentage of colon ... cancer cells with an already activated KRAS gene are
immune from the start and come to dominate as the other cancer cells are destroyed by the
inhibitor drug. The discovery
https://www.justice.gov/epstein/files/DataSet%209/EFTA00589683.pdf
EFTA01116328Set 9
4p1,459w
Oncology Department at Johns Hopkins University. The department was trying to understand
how the KRAS gene in colon-cancer cells becomes activated after inhibitor-drug therapy,
making the cells resistant ... growth of colon-cancer cells, Nowak and his team
showed that the KRAS gene is not actually activated or "switched on" by inhibitor therapy;
rather, a small percentage of colon ... cancer cells with an already activated KRAS gene are
immune from the start and come to dominate as the other cancer cells are destroyed by the
inhibitor drug. The discovery
https://www.justice.gov/epstein/files/DataSet%209/EFTA01116328.pdf
Oncology Department at John Hopkins University. The Department was trying to
understand how the KRAS gene in colon cancer cells becomes activated after inhibitor drug
therapy, making the cells resistant ... drug, (which typically target a protein receptor), Nowak and his team, showed how the
KRAS gene is not actually activated or 'switched on' from inhibitor drugs but rather a small ... percentage of colon cancer cells with an already activated KRAS gene are immune from the
start and evolve to predominance as the other cancer cells are destroyed by the inhibitor
https://www.justice.gov/epstein/files/DataSet%209/EFTA01128840.pdf
Oncology Department at [(John Hopkins University]]. The Department was trying to understand how the
KRAS gene in colon cancer cells becomes activated after inhibitor drug therapy, making the cells
resistant ... mathematical model of colon cancer cell growth, Nowak and his team, showed how the
KRAS gene is not actually activated or 'switched on' from inhibitor drugs but rather a small ... percentage
of colon cancer cells with an already activated KRAS gene are immune from the start and evolve to
predominance as the other cancer cells are destroyed by the inhibitor
https://www.justice.gov/epstein/files/DataSet%209/EFTA01131088.pdf
EFTA01116320Set 9
0p1,569w
Oncology Department at Johns Hopkins University. The department was trying to understand
how the KRAS gene in colon-cancer cells becomes activated after inhibitor-drug therapy,
making the cells resistant ... growth of colon-cancer cells, Nowak and his team
showed that the KRAS gene is not actually activated or "switched on" by inhibitor therapy;
rather, a small percentage of colon ... cancer cells with an already activated KRAS gene are
immune from the start and come to dominate as the other cancer cells are destroyed by the
inhibitor drug. The discovery
https://www.justice.gov/epstein/files/DataSet%209/EFTA01116320.pdf
EFTA01071423Set 9
3p1,589w
Oncology Department at
John Hopkins University. The Department was trying to understand how the KRAS gene in colon cancer
cells becomes activated after inhibitor drug therapy, making the cells resistant ... mathematical model of colon cancer cell growth, Nowak and his team, showed how the
KRAS gene is not actually activated or 'switched on' from inhibitor drugs but rather a small ... percentage
of colon cancer cells with an already activated KRAS gene are immune from the start and evolve to
predominance as the other cancer cells are destroyed by the inhibitor
https://www.justice.gov/epstein/files/DataSet%209/EFTA01071423.pdf
EFTA01961023Set 10
4p1,570w
Oncology Department at Johns Hopkins University. The department was trying to understand
how the KRAS gene in colon-cancer cells becomes activated after inhibitor-drug therapy, making
the cells resistant ... growth of colon-cancer cells, Nowak and his team
showed that the KRAS gene is not actually activated or "switched on" by inhibitor therapy;
rather, a small percentage of colon ... cancer cells with an already activated KRAS gene are immune
from the start and come to dominate as the other cancer cells are destroyed by the inhibitor drug.
The discovery
https://www.justice.gov/epstein/files/DataSet%2010/EFTA01961023.pdf
Oncology Department at John Hopkins University. The Department was trying to
understand how the KRAS gene in colon cancer cells becomes activated after inhibitor drug
therapy, making the cells resistant ... drug, (which typically target a protein receptor), Nowak and his team, showed how the
KRAS gene is not actually activated or 'switched on' from inhibitor drugs but rather a small ... percentage of colon cancer cells with an already activated KRAS gene are immune from the start
and evolve to predominance as the other cancer cells are destroyed by the inhibitor
https://www.justice.gov/epstein/files/DataSet%2010/EFTA01898400.pdf
EFTA01966271Set 10
3p1,591w
Oncology Department at John Hopkins
University. The Department was trying to understand how the KRAS gene in colon cancer cells becomes
activated after inhibitor drug therapy, making the cells resistant ... mathematical model of colon cancer cell growth, Nowak and his team, showed how the
KRAS gene is not actually activated or 'switched on' from inhibitor drugs but rather a small ... percentage of
colon cancer cells with an already activated KRAS gene are immune from the start and evolve to
predominance as the other cancer cells arc destroyed by the inhibitor
https://www.justice.gov/epstein/files/DataSet%2010/EFTA01966271.pdf
EFTA01964817Set 10
4p1,460w
Oncology Department at Johns Hopkins University. The department was trying to understand
how the KRAS gene in colon-cancer cells becomes activated after inhibitor-drug therapy, making
the cells resistant ... growth of colon-cancer cells, Nowak and his team
showed that the KRAS gene is not actually activated or "switched on" by inhibitor therapy;
rather, a small percentage of colon ... cancer cells with an already activated KRAS gene are immune
from the start and come to dominate as the other cancer cells are destroyed by the inhibitor drug.
The discovery
https://www.justice.gov/epstein/files/DataSet%2010/EFTA01964817.pdf
Oncology Department at [[John Hopkins University)]. The Department was trying to understand how the
KRAS gene in colon cancer cells becomes activated after inhibitor drug therapy, making the cells
resistant ... mathematical model of colon cancer cell growth, Nowak and his team, showed how the
KRAS gene is not actually activated or 'switched on' from inhibitor drugs but rather a small ... percentage of
colon cancer cells with an already activated KRAS gene are immune from the start and evolve to
predominance as the other cancer cells are destroyed by the inhibitor
https://www.justice.gov/epstein/files/DataSet%2010/EFTA01898397.pdf
EFTA02444849Set 11
152p72,123w
Clinstan'r are akin to the apple in the Garden of
,,kras. ,... 4 n • offitra=
B, i bo,ail Eli I witIsible1111=-1'
i ( Fir; ab...1 Eden, responsible
https://www.justice.gov/epstein/files/DataSet%2011/EFTA02444849.pdf